已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study

阿帕蒂尼 医学 肝细胞癌 内科学 联合疗法 胃肠病学 不利影响 肿瘤科 酪氨酸激酶抑制剂 实体瘤疗效评价标准 肝癌 无进展生存期 癌症 化疗 临床研究阶段
作者
Zeran Yang,Guang Chen,Ye Cui,Xiao Guo-wen,Ting Su,Jianan Yu,Zhiyuan Zhang,Yanjing Han,Kai-Lan Yang,Long Jin
出处
期刊:Cancer Biology & Therapy [Informa]
卷期号:20 (3): 321-327 被引量:34
标识
DOI:10.1080/15384047.2018.1529099
摘要

As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft应助liulongchao采纳,获得10
刚刚
直率如容发布了新的文献求助10
3秒前
不无聊的从梦完成签到 ,获得积分10
4秒前
5秒前
张大德完成签到,获得积分10
6秒前
含蓄老黑完成签到,获得积分10
6秒前
小梁发布了新的文献求助10
7秒前
7秒前
Hello应助PONY采纳,获得10
8秒前
张大德发布了新的文献求助10
12秒前
13秒前
jia应助平淡的路人采纳,获得20
14秒前
小秦同学发布了新的文献求助10
14秒前
世佳何完成签到,获得积分10
15秒前
chen发布了新的文献求助10
16秒前
光亮的天真完成签到 ,获得积分10
16秒前
19秒前
22秒前
彭于晏应助忧虑的羊采纳,获得10
23秒前
文章多多完成签到 ,获得积分10
24秒前
星辰大海应助小一采纳,获得10
24秒前
25秒前
25秒前
在水一方应助石头慢半拍采纳,获得10
26秒前
施含莲发布了新的文献求助10
26秒前
岸在海的深处完成签到 ,获得积分10
26秒前
28秒前
雪时晴发布了新的文献求助10
31秒前
31秒前
32秒前
liulongchao发布了新的文献求助10
32秒前
34秒前
汉堡包应助橘子采纳,获得10
36秒前
溦昼发布了新的文献求助10
36秒前
36秒前
Lucas应助香山叶正红采纳,获得10
37秒前
37秒前
天涯霜雪完成签到,获得积分10
38秒前
小秦同学完成签到,获得积分10
38秒前
39秒前
高分求助中
Spray / Wall-interaction Modelling by Dimensionless Data Analysis 2000
Mixed-anion Compounds 600
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Earth System Geophysics 500
Aspects of Babylonian celestial divination: the lunar eclipse tablets of Enūma Anu Enlil 500
Geochemistry, 2nd Edition 地球化学经典教科书第二版 401
2024 Medicinal Chemistry Reviews 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3200500
求助须知:如何正确求助?哪些是违规求助? 2850228
关于积分的说明 8071464
捐赠科研通 2514096
什么是DOI,文献DOI怎么找? 1346837
科研通“疑难数据库(出版商)”最低求助积分说明 640265
邀请新用户注册赠送积分活动 610272